LGND — Ligand Pharmaceuticals Incorporated Share News
0.000.00%
Last trade - 00:00- $5.95bn
- $5.72bn
- $215.02m
Brief: Ligand’S Partner Viking Therapeutics Announces Positive Top-Line Results From Phase 2B Voyage Study
Brief: Ligand Pharmaceuticals Q1 EPS $2.33
Ligand Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ligand Reports First Quarter 2023 Financial Results
Ligand Pharmaceuticals Inc expected to post earnings of 89 cents a share - Earnings Preview
Biodexa Pharma - Exercise of Warrants and Issue of Equity
Brief: Ligand Pharmaceuticals Inc Says Does Not Hold Any Deposits Or Securities Or Maintain Any Accounts At SVB
Ligand Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Ligand Pharmaceuticals Inc expected to post earnings of $1.19 a share - Earnings Preview
Brief: Novan Submits NDA To U.S. FDA For Berdazimer Gel, 10.3%
Brief: Ligand Pharmaceuticals Issues 2023 Financial Guidance
Ligand Pharmaceuticals down as CEO John Higgins retires
Brief: Ligand Pharmaceuticals Names Director Todd C. Davis As CEO
Ligand Pharma up on raised 2022 sales forecast
Ligand Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Ligand Pharmaceuticals Says Quarterly Diluted Net Income Per Share $0.02
Brief: Ligand Pharmaceuticals Inc Expects FY22 Total Revenue Between $184 Mln To $189 Mln
Ligand Pharmaceuticals Inc expected to post earnings of 43cents a share - Earnings Preview
Ligand up after FDA nod for partner Janssen's blood cancer therapy